Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH276 in RAS-mutant advanced solid tumors
NCT07198321Phase 2Not yet recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH276 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), solid tumor, sponsored by GenFleet Therapeutics. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
GFH276
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT07198321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198321.